Inventor · disambiguated record
Antonio J. Grillo-Lopez
Also filed as: GRILLO-LOPEZ ANTONIO · GRILLO-LOPEZ ANTONIO J · GRILLO-LÓPEZ ANTONIO J
13 granted patents·20 pending applications·773 citations·filing 1999–2018
94Inventor score
Top patents by PatentIndex Score
33 records- 0198US6455043B1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 1999·Granted Sep 24, 2002·351 cites·15 claims
- 0296US7820161B1Treatment of autoimmune diseasesBIOGEN IDEC INC·Filed 2000·Granted Oct 26, 2010·133 cites·12 claims
- 0395US8545843B2Treatment of vasculitisCURD JOHN G·Filed 2010·Granted Oct 1, 2013·49 cites·12 claims
- 0495US8329172B2Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyGRILLO-LOPEZ ANTONIO J·Filed 2007·Granted Dec 11, 2012·59 cites·1 claims
- 0592US8557244B1Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibodyWHITE CHRISTINE·Filed 2000·Granted Oct 15, 2013·54 cites·2 claims
- 0690US7682612B1Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibodyBIOGEN IDEC INC·Filed 1999·Granted Mar 23, 2010·88 cites·60 claims
- 0788US8206711B2Treatment of chronic lymphocytic leukemia using anti-CD20 antibodiesWHITE CHRISTINE A·Filed 2009·Granted Jun 26, 2012·23 cites·9 claims
- 0886US9296821B2Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodiesGRILLO-LÓPEZ ANTONIO J·Filed 2012·Granted Mar 29, 2016·8 cites·6 claims
- 0983US8821873B2Treatment of diffuse large-cell lymphoma with anti-CD20 antibodyBIOGEN IDEC INC·Filed 2013·Granted Sep 2, 2014·4 cites·5 claims
- 1079US10113000B2Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyBIOGEN INC·Filed 2016·Granted Oct 30, 2018·1 cites·8 claims
- 1179US9504744B2Treatment of diffuse large-cell lymphoma with anti-CD20 antibodyBIOGEN INC·Filed 2014·Granted Nov 29, 2016·2 cites·16 claims
- 1278US10400043B2Treatment of diffuse large-cell lymphoma with anti-CD20 antibodyBIOGEN INC·Filed 2017·Granted Sep 3, 2019·1 cites·1 claims
- 1366US2018264107A1Treatment of autoimmune diseasesGENENTECH INC·Filed 2018·Application pending·0 cites
- 1465US2014056887A1Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodyBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 1564US2014134164A1Treatment of multiple sclerosisBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 1664US2017037140A1Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodyBIOGEN INC·Filed 2016·Application pending·0 cites
- 1764US2013330332A1Treatment of pemphigusBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 1864US2013273039A1Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodyBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 1963US2013273042A1Treatment of multiple sclerosisBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 2062US9993550B2Treatment of pemphigusGENENTECH INC·Filed 2015·Granted Jun 12, 2018·0 cites·7 claims
- 2162US2013084289A1Treatment of multiple sclerosisGENENTECH INC·Filed 2012·Application pending·0 cites
- 2261US2009074760A1Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplantGRILLO-LOPEZ ANTONIO J·Filed 2008·Application pending·0 cites
- 2361US2014363424A1Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplantBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 2459US2012201818A1Treatment of multiple sclerosisCURD JOHN G·Filed 2012·Application pending·0 cites
- 2559US2015183882A1Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodyBIOGEN IDEC INC·Filed 2015·Application pending·0 cites
- 2658US2017037139A1Treatment of diffuse large-cell lymphoma with anti-cd20 antibodyBIOGEN INC·Filed 2016·Application pending·0 cites
- 2757US2013273041A1Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplantGRILLO-LOPEZ ANTONIO J·Filed 2013·Application pending·0 cites
- 2857US2003206903A1Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 2957US2004213784A1Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplantIDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 3055US2003026804A1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 3154US2011165159A1Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplantBIOGEN IDEC INC·Filed 2011·Application pending·0 cites
- 3253US2010003252A1Blocking immune response to a graftGENENTECH INC·Filed 2009·Application pending·0 cites
- 3339US2002009444A1Intrathecal administration of rituximab for treatment of central nervous system lymphomasIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Antonio J. Grillo-Lopez files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →